For patients with diabetes, the challenge of managing their therapy can be alleviated with proper, quality education. For more than a decade, Novasyte has partnered with many of the largest, global medical device, diagnostic, and pharmaceutical organizations, providing specialized education with the highest-quality certified product trainers.
Novasyte is honored to announce that we ranked 1,692 overall and 125 in the healthcare category on the 2018 Inc. 5000 List of Fastest-Growing Private Companies in America. This marks the sixth consecutive year achieving this recognition, putting us on an exclusive short list of only six percent of companies acknowledged for maintaining this level of continued growth over the years, including Microsoft, Timberland, Vizio, Intuit, Chobani, Oracle and Zappos.com.
With increased pressures to reduce internal SG&A costs, accelerate the pace of business, and increase process efficacies, manufacturers are continually investing in third-party partnerships where innovation is at the forefront of service delivery.
The medtech industry is no stranger to change.
Increasing customer demands coupled with reduced budgets, higher targets and new technologies are requiring organizations to think differently and pivot seamlessly — all while balancing risk.
A new challenge the medtech industry is facing is how to plan for the aging workforce crisis among field service engineers.
Topics: Field Technical
Novasyte is proud to welcome its newest member of the corporate team, Odessa Woodburn, who officially started in her role of Travel and Expense Coordinator on Monday, July 9th.
Learn more about Odessa with her Q&A session below.
Novasyte is proud to welcome its newest member of the corporate team, Joshua Hogan, who officially started in his role of Healthcare Recruiter on Monday, July 9th.
Learn more about Joshua with his Q&A session below.
Improving the patient experience and measuring their satisfaction is becoming increasingly
important to facilities and manufacturers. Not only is patient satisfaction one of the three essential dimensions of the Institute for Health Improvement (IHI) Triple Aim, but the scores are also key performance metrics under the 2016 Center for Medicare and Medicaid Services (CMS) Hospital Value-Based Purchasing (VBP) Program.
Pharmaceutical manufacturers today are facing increasing pressures from The Trump Administration to reduce the cost of drug prices.
Announced on Wednesday of this week, Novartis indicated they would not be raising prices on its products for the remainder of 2018.1 They are joining Pfizer, whose chief executive officer, Ian Read, announced on July 10 that the company would delay increasing the prices on dozens of drug products until 2019, following President Trump publicly spotlighting the firm the day prior.2
This follows the initial statement from The Trump Administration in May 2018 regarding a comprehensive blueprint strategy to lower drug prices.
As a partner to many of the largest, global medtech companies for more than a decade, Novasyte has gained a strong understanding of the evolving healthcare landscape and trends in nurse staffing. With the consistent rotation of nurses in hospital systems, manufacturers are adapting to the staffing changes and optimizing their education methods to ensure successful medical device conversions.
For many medtech manufacturers, commercializing products into a new healthcare facility brings a series of opportunities and challenges, including:
- The need to provide proof of product efficacy and cost effectiveness,
- The need to deliver new product into the facility quickly,
- The need to align with facility leadership on the strategic direction to implement, and
- The need to train the facility’s end-users to support adoption.